

MOTP CLINICAL DIRECTIVES

Program:	Liver Transplantation		
Title:	Liver Transplant Recipient Management: Immunosuppression		
Approved by:	Paul Marotta, Anton Skaro	Last Review and Approval by:	Anouar Teriaky
Original Issue:	April 30, 2019	Last Review:	February 02, 2023
		Last Revision:	

	0-3 months	3-12 months	1-5 years	>5 years	
Low Risk Recipients	<ul style="list-style-type: none"> • Non autoimmune etiology of liver disease, first transplant, uneventful 1st 3 months, normal renal function, NDD or LD donor • Monotherapy after 3 months with Tacrolimus – if Tacrolimus not tolerated, consider Cyclosporine 				
	Induction	Corticosteroids			
	Prograf® / Tacrolimus	Trough target: 6-10 ng/mL	Titrate to target 5 ng/mL	Titrate to target 3 ng/mL	Low dose Drug level less important
	Cyclosporine	If Tacrolimus not tolerated Start 100-200 mg BID Trough target: 150-200 ng/mL	Titrate to target 100 ng/mL	Titrate to target 50-100 ng/mL	Low dose Drug level less important
	MMF / CellCept®	Off	Off	Off	Off
	Prednisone	Start 20 mg OD Liver Transplant Taper Protocol*	Off	Off	Off
	Sirolimus	Optional second line if required			

	0-3 months	3-12 months	1-5 years	>5 years	
High Risk Recipients	<ul style="list-style-type: none"> • AKI, retransplant, autoimmune diseases, previous rejection, DCD donor • Trial of conversion to monotherapy immunosuppression may be considered with close observation 				
	Induction	Corticosteroids & Simulect® (Basiliximab)			
	Prograf® / Tacrolimus	Trough target: 6-10 ng/mL	Titrate to target 5 ng/mL	Titrate to target 3 ng/mL	Low dose Drug level less important
	Cyclosporine	If Tacrolimus not tolerated Trough target: 150-200 ng/mL	Titrate to target 100 ng/mL	Titrate to target 50-100 ng/mL	Low dose Drug level less important
	MMF / CellCept®	1 g q12 hours as tolerated	1 g q12 hours as tolerated	1 g q12 hours as tolerated	1 g q12 hours as tolerated
	Prednisone	Start 20 mg OD Liver Transplant Taper Protocol*	Off	Off	Off
	Sirolimus	Optional second line if required			

Special patient populations:

- Patients with cancers:
 - Non-melanoma skin cancer, recurrent HCC, non-Hodgkin's lymphoma, lung cancer, RCC
 - Consider switching CNI to Sirolimus after 1 month
 - Patients transplanted for alcoholic liver disease or PSC are particularly at risk
- Patients with renal dysfunction:
 - Delay initiation of CNI and aim for low end of trough level target
 - Maintenance immunosuppression with MMF
 - Consider switching CNI to Sirolimus after 1 month

Prednisone Taper Protocol	
Start:	20 mg
Week 4:	15 mg
Week 6:	10 mg
Week 8:	5 mg
Week 12:	0 mg

This is a controlled document. Any documents in paper form must be used for reference purposes only. The s:drive copy must be considered the current document.

This protocol has been created specifically for London Health Sciences Centre (LHSC) and may not be applicable for other centres. This document is the intellectual property of LHSC. It is not to be shared or duplicated without permission.